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ARTICLE
Expression map of 78 brain-expressed mouse
orphan GPCRs provides a translational resource for
neuropsychiatric research
Aliza T. Ehrlich1,2, Grégoire Maroteaux2,5, Anne Robe1, Lydie Venteo3, Md. Tauﬁq Nasseef2,
Leon C. van Kempen4,6, Naguib Mechawar2, Gustavo Turecki2, Emmanuel Darcq2 & Brigitte L. Kieffer 1,2
Orphan G-protein-coupled receptors (oGPCRs) possess untapped potential for drug dis-
covery. In the brain, oGPCRs are generally expressed at low abundance and their function is
understudied. Expression proﬁling is an essential step to position oGPCRs in brain function
and disease, however public databases provide only partial information. Here, we ﬁne-map
expression of 78 brain-oGPCRs in the mouse, using customized probes in both standard and
supersensitive in situ hybridization. Images are available at http://ogpcr-neuromap.douglas.
qc.ca. This searchable database contains over 8000 coronal brain sections across
1350 slides, providing the ﬁrst public mapping resource dedicated to oGPCRs. Analysis with
public mouse (60 oGPCRs) and human (56 oGPCRs) genome-wide datasets identiﬁes 25
oGPCRs with potential to address emotional and/or cognitive dimensions of psychiatric
conditions. We probe their expression in postmortem human brains using nanoString, and
included data in the resource. Correlating human with mouse datasets reveals excellent
suitability of mouse models for oGPCRs in neuropsychiatric research.
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G protein-coupled receptors (GPCRs) represent the largestreceptor family for drug development in medicine (seeGPCR database at http://www.guidetopharmacology.org/)1.
As of November 2017, the 475 FDA approved drugs, which activate
or block GPCRs, account for nearly 30% of all pharmaceuticals in
current use2–4. These drugs in fact target only 27% of known
GPCRs, with aminergic (dopamine, serotonin), cannabinoid and
opioid receptors being most prominent targets for the central
nervous system3. About 400 non-odorant GPCR genes have been
identiﬁed in the genome, among which a subset of approximately
130 remain orphan GPCRs (oGPCRs), meaning that their endo-
genous ligand has not been identiﬁed1,3–6. Importantly, almost half
of oGPCRs are expressed in the brain3,7,8 and, as are orphan
neuropeptides9, each neural oGPCR represents an unprecedented
opportunity to address brain function and disease10,11.
All GPCRs, including oGPCRs, are prime drug targets, as these
receptors are easily accessible at the cell surface, and recent drug
design strategies utilize allostery, bias or structure-based docking
approaches to create new drugs12–14. Hence oGPCRs, in princi-
ple, have strong potential for drug design, however their function
in the brain is poorly understood and, overall, these receptors are
understudied15. In a few cases only, oGPCR genes are linked to a
disease3, surrogate ligands have been developed (for a recent
example see ref. 16), or a phenotype is reported after gene
knockout and/or overexpression in mice (reviewed in the
ref. 5,17), but overall the potential of oGPCRs for neuroscience
and neuropsychiatry has not been systematically explored.
An essential ﬁrst step toward this goal is to establish the
expression pattern of oGPCR transcripts throughout the brain.
Notable is the case of GPR88, whose striatal-enriched distribution
described a decade ago18–21 attracted attention in both academia
and industry. The Gpr88 gene deletion in mice revealed multiple
roles in behaviors related to striatal22–26 and sensory
cortical22,27,28 functions with potential implications for both
neurological and psychiatric disorders. Drug discovery efforts
show very recent success for GPR88 agonist development29,30,
and a ﬁrst human genetic study reported association between
GPR88 variants and brain pathology, including learning and
movement deﬁcits31,32. The case of GPR88, or the example of
GPR5233,34 demonstrate that elucidating oGPCR brain expres-
sion proﬁles is paramount to recognize the potential therapeutic
value for any given oGPCR.
Two publicly available databases, which cover the entire gen-
ome, report microarray-based gene expression proﬁling of
selected mouse (http://brainstars.org/multistate/)35, and human
(Allen Institute, http://human.brain-map.org/) brain regions36.
Mining for oGPCR expression in these resources is possible,
although many oGPCRs remain below detection thresholds and
the anatomical precision is poor. Two other sources of infor-
mation are available, which report spatial transcript distribution
for thousands of genes in the mouse brain using in situ hybri-
dization (ISH) (Allen Institute 20,000 genes see ref. 37 and
GENSAT 5000 genes see ref. 38), but in these approaches low
sensitivity and high throughput strategies often hampers the
detection of low abundant transcripts, as is the case for most
oGPCRs. A single study described the distribution of all known
GPCR transcripts using qPCR in samples from mouse tissues,
including essentially peripheral tissues and some brain regions7.
In this case there was no speciﬁc focus on orphan GPCRs, and
their spatial distribution in the brain.
To tackle brain oGPCR anatomy in the brain, we ﬁne-map
their expression in the mouse brain using dedicated probes in two
complementary in situ hybridization (ISH) approaches, and cre-
ate a database of all images, posted as an open-access resource at
http://ogpcr-neuromap.douglas.qc.ca. Further, we correlate
oGPCR expression scores with data from the two most
comprehensive public databases (mouse http://brainstars.org/
multistate/ and human http://human.brain-map.org/) for cross-
validation and to probe cross-species information. These analyses
guide further selection of an oGPCR subgroup with expression in
key brain centers for cognition, motivational drive and emotional
processing, which we test in postmortem human brain samples
(also in the database) to evaluate appropriateness of mouse
models and the potential to address oGPCR contributions in
neuropsychiatric disorders.
Results
The oGPCR-neuromap database. The process for creating the
oGPCR database is summarized in Fig. 1. Initial information
came from a previous qPCR-based expression study of non-
odorant GPCRs in central and peripheral adult mouse tissues7.
From this report, we compiled a list of 92 oGPCRs that were
detected in the brain, among which about 50% where present in
Searchable Brain oGPCR database generation
78 oGPCRs mapping throughout  mouse brain
25 oGPCRs quantified in 14 human brain regions















Samples  ~120 from 4 to 13
individuals
Fig. 1 Generation of the oGPCR-neuromap. 92 brain oGPCRs were selected
from a previous study reporting GPCR tissue distribution in mice7. Coronal
sections were prepared from 32 mouse brains, and customized probes
were generated by plasmid production and probe transcription for DIG
in situ hybridization (ISH), and by the manufacturer for RNAscope ISH. For
both approaches, 50 sections across 9 slides were assayed for each brain
oGPCR, representing ~200 ISH experiments in total. 78 oGPCRs were
merited for semi-quantitative analysis (Fig. 2). For these 78 oGPCRs, ~160
experiments containing 1350 slides of 8000 sections are deposited online
in a searchable website http://ogpcr-neuromap.douglas.qc.ca. 25 oGPCRs
were selected (Supplementary Table 2) for proﬁling in the human brain.
Approval was obtained from the institutional review board. Roughly 120
human samples were prepared from 4 to 13 postmortem individuals to span
14 brain regions, used for RNA preparation and quality controlled.
Customized nanoString probes were designed to target the 25 oGPCR
transcripts, which were quantiﬁed in all the 120 samples. Raw data from
each individual sample are also deposited in the oGPCR-neuromap resource
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brain only. Mouse brains were sectioned coronally and processed
with customized probes to target brain oGPCRs in both digox-
igenin (DIG)-ISH (Supplementary Data 1) and RNAscope ISH
experiments. Control probes were included in all the ISH
experiments (Supplementary Figure 1a) and about 50 brain sec-
tions spanning the brain were labeled for each probe. All recep-
tors were studied, however data for only 78 oGPCRs are shown
and discussed here. We eliminated a few candidates when tech-
nical problems impeded ISH image analysis. In the ﬁnal collec-
tive, 51 oGPCRs are rhodopsin-like (class A), 18 oGPCRs belong
to the adhesion family (class B), 3 are members of the glutamate
family (class C), and 6 oGPCRs belong to other classes such as
frizzled5,39–41. A selection of 25 oGPCRs (see below) was further
studied in 120 samples from 4 to 13 adult human individuals,
including 14 brain regions and using custom-made probes by
digital gene expression nanoString technology.
Overall, image datasets from almost 160 experiments, on over
8000 coronal mouse brain sections across 1350 slides are
uploaded in the database. Original slide scanner images can be
searched by gene name or technique as well as representative
images for control probes for each technique, DIG-ISH or
RNAscope ISH. The human individual subject data are also
deposited in the resource. This open access resource is now
available to researchers and clinicians online at http://ogpcr-
neuromap.douglas.qc.ca.
Clustering mouse oGPCR expression levels using DIG-ISH
data. To further exploit the mouse DIG-ISH resource, we semi-
quantiﬁed the ISH signal for each oGPCR by manual observation,
and data from two independent observers were compared. Dis-
crepancy was rare, but in this case data were confronted and
agreed for consistency. Scoring was performed across 16 regions
selected to span the entire brain. Scoring for each oGPCR was
done on a scale of 4 levels of expression high (3.5), moderate



































































































































































































Fig. 2 Clustering oGPCR distribution in the mouse brain. a, b Semi quantiﬁcation of DIG-ISH mapping of oGPCRs in the adult mouse brain. a Heatmap
showing hierarchical clustered distribution of oGPCRs (Gpr17 was not scored due to unvaried expression) mapped by scoring ISH images across 16 brain
regions in the mouse. Gene cluster 1 (GC1) principally includes widespread oGPCRs with strong (GC1a) or moderate (GC1b) expression across the brain.
Gene cluster 2 (GC2) essentially contains localized oGPCRs with moderate to high (GC2a and b1) or widespread low expression patterns (GC2a and b2) as
well as absent oGPCRs (GC2b2). Color bar indicate 4 scoring levels of expression high (3.5, orange), moderate (2.5, brown), low (1.5, greyish blue) or
absent (0.5, blue). b Pie charts illustrate oGPCR distribution (high/moderate/low/absent) according to the brain region (See Supplementary Data 2 for
oGPCR listings). Annotated brain regions: OB, olfactory bulb; Ctx, cortex; ACB, nucleus accumbens; CP, caudate putamen; HPF, hippocampal formation;
BLA, basal-lateral amygdala; CeA, central extended amygdala; Hy, hypothalamus; Hb, habenula;, Th, thalamus; Mb, midbrain; VTA, ventral tegmental area;
SN, substantia nigra; DRN, dorsal raphe nucleus; Mb-other (general midbrain excluding aforementioned areas); Pn, pons; Med, medulla; Cer, cerebellum
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between probes, scoring was performed based on relative inten-
sities across all brain sections for each probe dataset, in a within
design. As an example, the striatal receptor Gpr88 was absent in
olfactory bulb (OB), low in cortex (Ctx), moderate in nucleus
accumbens (ACB) and high in caudate putamen (CP) (Supple-
mentary Figure 1b, top), in agreement with previous reports20–
22,28,42. Unsupervised hierarchical gene clustering of the DIG-ISH
scoring revealed 2 principal gene cluster nodes, GC1 and GC2,
the former containing oGPCRs with widespread distribution and
the latter containing those with highly restricted, low or unde-
tectable expression (Fig. 2a).
GC1 is primarily composed of genes with broad expression
throughout mid- to forebrain and contains 2 groups. GC1a
includes Gprc5c, Gpr37, and Gpr63, all showing moderate to high
expression in Ctx, basolateral amygdala (BLA), habenula (Hb),
thalamus (Th), and midbrain (Mb)—ventral tegmental area
(VTA)/substantia nigra (SN). GC1b includes 3 clusters with high
expression in BLA (Celsr3, Gpr56, and Gpr26), or in Ctx and Th
(Gpr123, Bai1), and moderate expression across Ctx, Hb, Th, and
cerebellum (Cer) (Gpr83, Gpr155, and Gprc5b). Gpr48 is isolated
displaying highest expression in Hb.
More localized oGPCRs were found throughout the GC2 node.
Prominent clusters in GC2a are as follows: Gpr88 and Gpr161
form a small cluster, sharing expression in ACB and central
extended amygdala (CeA). Additionally, Gpr107, Gpr165, and
Gpr150 are expressed in medulla (Med) and pons (Pn), a region
containing noradrenergic nuclei (locus coeruleus). Next, adhesion
receptor Gpr98 shows high expression in the serotonergic dorsal
raphe nucleus (DRN). Lastly, a BLA cluster (Celsr2 Gpr68,
Gpr162) is adjacent to cortico-hippocampal and amygdalar
oGPCRs (Gpr27, Gpr39, Lphn3, Bai2). In GC2b1, 2 oGPCRs
show remarkably localized expression, Gpr50 only in Hy and
Gpr151 highly enriched in the Hb. The last subgroup GC2b2,
consists of 27 oGPCRs, 16 with low expression, the exception
being Gpr22 with moderate expression in Ctx, and 11 oGPCRs
were undetectable by this ISH method.
We examined the distribution of oGPCRs across the four
categories (high/moderate/low/absent) in the 16 brain regions
(Fig. 2b). Depending on the brain region 45–77% oGPCRs were
detected in each region and, notably, OB, Ctx, HPF, BLA, and
CeA expressed a large part (49–59) of the entire oGPCR group
(see oGPCR details in Supplementary Data 2). We searched for
potential cell types expressing the 78 oGPCRs using the public
RNA-Seq database of adult mouse cortical puriﬁed cells (https://
web.stanford.edu/group/barres_lab/brain_rnaseq.html)43 and
found 21 neuronal, 10 in astrocytes, 10 microglial, 8 endothelial,
11 oligodendrocytic oGPCRs, while 17 oGPCRs were virtually
undetectable in this database (Table 1). In conclusion, the semi-
quantiﬁcation demonstrates highly distinguishable expression
patterns, ranging from ubiquitous to very localized, and points at
a number of oGPCRs with highly spatially restricted distribution
that may be indicative of specialized brain functions.
Detecting additional oGPCRs with supersensitive RNAscope
ISH. Not all the oGPCR transcripts could be detected by DIG-
ISH (see Fig. 2a, GC2b2). Since GPCRs are notoriously difﬁcult to
detect because of overlapping sequence homology and low
expression, we improved our chances of successful oGPCR
detection by repeating the entire mapping experiment using
another ISH approach. RNAscope is a highly sensitive ISH
method that robustly ampliﬁes the signal of individual RNA
molecules with no cross-hybridization44. In addition, using a
second method would conﬁrm ﬁndings from the standard DIG-
ISH experiment.
For all oGPCRs dedicated probes were designed and control
probes were included in each experiment (Supplementary Fig. 1a,
bottom). For the majority of oGPCRs in this study, detection was
achieved at a similar level to DIG-ISH as shown for Gpr88
(Supplementary Fig. 1b, bottom) and Gpr50, absent in PFC and
ACB but remarkable in Hy (compare Gpr50 in Hy in Fig. 2a and
Supplementary Fig. 2). For some oGPCRs, RNAscope increased
regional identiﬁcation, as seen with Gpr68 in PFC, CP, and ACB,
which was low or absent with DIG-ISH (compare Fig. 2a and
Supplementary Fig. 2). For the 16 oGPCRs with only low
detection in DIG-ISH, 11 oGPCRs had improved detection with
RNAscope. These included, Gpr139 highly expressed in PFC, CP
and MHb, Gpr149 with moderate to low expression in ACB, CeA
and VTA, and Gpr162 was highly detectable in PFC moderate in
CP and low in VTA (Supplementary Fig. 2).
Thus, the two distinct ISH methods yielded comparable
distribution of oGPCR expression, cross-validating our results,
and added highly sensitive detection for low abundant oGPCRs.
Correlating ISH data with public mouse and human datasets.
Next, we converted the semi-quantiﬁed ISH data into Z-scores
(see methods) to compare data from this study with available
datasets. A ﬁrst mouse-mouse data comparison was important
for validation. We searched for publicly available mouse tran-
scriptome databases, and selected the BrainStars platform (http://
brainstars.org/) having the highest number of oGPCRs. We
retrieved the DNA-microarray data obtained from micro-
dissected mouse brain samples35, and performed correlation
analyses for each gene. We ﬁrst tested the extent to which
expression proﬁles differ between the two mouse datasets using
Student’s t-tests (Supplementary Table 1) and found that dis-
tribution proﬁles for 60 oGPCRs across 12 brain regions in the
two datasets were not statistically different. We then probed
similarities between expression patterns using Pearson correla-
tion analysis and found that 80% of oGPCRs display positive
Table 1 oGPCR cell subtype
Neurons Celsr2, Celsr3, Gpr12, Gpr21, Gpr22, Gpr26, Gpr27, Gpr45, Gpr61, Gpr64, Gpr83, Gpr85, Gpr88, Gpr123, Gpr135, Gpr149,
Gpr151, Gpr161, Gpr162, Gpr173, and Mchr1
Astrocytes Bai2, Bai3, Celsr1, Gpr3, Gpr19, Gpr48, Gpr51, Gpr63, Gpr98, Smoh
Microglia Emr1, Fpr1, Gpr56, Gpr107, Gpr108, Gpr137b, Gpr153, Gpr165, Gpr175, Gpr183
New oligodendrocytes Gpr15, Gpr17, Gpr155, Gpr176
Myelinating oligodendrocytes Gpr37, Gprc5b
OPCs Bai1, Gpr49, Gpr75, Gpr125, Lphn3, Mrge
Endothelial Eltd1, Gpr30, Gpr116, Gpr124, Gpr146, Gpr182, Gprc5c, Lphn2
Virtually undetectable Gpr1, Gpr2, Gpr39, Gpr50, Gpr68, Gpr82, Gpr87, Gpr101, Gpr111, Gpr139, Gpr150, Gpr171, Mas1, Pgr15l, Taar4, Taar9, Taar6
RNA-Seq database of puriﬁed neurons, astrocytes, microglia, endothelial cells, pericytes, and various maturation states of oligodendrocytes from mouse cortices reveal the cell subtype of indicated
oGPCRs (https://web.stanford.edu/group/barres_lab/brain_rnaseq.html)43. For clarity, each oGPCR is shown in the category with the highest Fragments Per Kilobase of transcript per Million (FPKM)
reads, and is classiﬁed as virtually undetectable when FPKM is below 1.0
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Pearson coefﬁcients (r), among which nearly half (31%) show
statistically signiﬁcant similarity (Pearson correlation, r from
0.5788 to 0.99609, P values from 0.0486 to <0.0001 also see
Supplementary Table 3) (Fig. 3a). Only 20% of oGPCRs showed
inversely correlated expression patterns, and these trends
remained non-signiﬁcant (P > 0.05). Overall therefore, the two
mouse datasets showed highly comparable distribution of
oGPCR expression.
A mouse–human data comparison is a further critical step in
the context of drug development and the relevance of animal
models. For cross-species analysis, we compared 56 oGPCR genes
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(http://human.brain-map.org/36) with mouse DIG-ISH data
from this study, and across 15 brain regions. With the exception
of Gpr68, oGPCR expression proﬁles did not differ statistically
using the Student’s t-test (Supplementary Table 1). Further,
Pearson correlation analysis indicated that 70% of oGPCRs
showed positively correlated expression patterns, of which 18%
showed statistical signiﬁcance between our own and human data
(Pearson correlation, r from 0.6016 to 0.9964, P values from
0.0165 to <0.0001 also see Supplementary Table 3 and Fig. 3b).
Otherwise 30% of oGPCRs were inversely correlated, with only
Gpr161 reaching statistical signiﬁcance. Together, and as
expected, cross-species comparison shows less similarity than
within-species comparison, and suggests that expression patterns
of Gpr68 and Gpr161 in particular may largely differ across
mouse and human.
We ﬁnally identiﬁed oGPCRs with high similarity in transcript
distribution both within and across species, by combining mouse-
mouse and mouse-human correlations in a new Pearson
correlation analysis. The overall comparison yielded a Pearson
coefﬁcient that was statistically signiﬁcant (Pearson correlation r
= 0.4987, P= 0.000092, 95% CI 0.2714–0.6733) and highlighted a
number of oGPCRs commonly found in both mouse–mouse and
mouse–human data (Fig. 3c). In conclusion, correlation analyses
identiﬁed 34 oGPCRs whose expression proﬁle in our study
correlates well with existing data, an information that extends in-
depth oGPCR ﬁne-mapping of the present resource.
Focusing on 25 oGPCRs and mouse brain function. To
exemplify the potential of the oGPCR-neuromap for target dis-
covery in the area of neuropsychiatric diseases, we next selected a
sub-group of 25 oGPCR transcripts, to be examined further in the
human brain. Criteria were as follows, localized rather than
widespread expression for their potential to have restricted over
wide-ranging functions (Supplementary Table 2, Column II),
high correlation coefﬁcients between mouse DIG-ISH and
BrainStars (Supplementary Table 2, Column III; Fig. 3a), high
correlation coefﬁcients between mouse DIG-ISH and human
Allen brain (Supplementary Table 2, Column IV; Fig. 3b) and low
most number of existing original publications based on PubMed
records (Supplementary Table 2, Column V). The table identiﬁed
25 oGPCRs ﬁtting our criteria (Supplementary Table 2 oGPCRs
in gold; Fig. 3c in purple). In this collection of 18 Class A, 4 Class
B, 2 Class C and a single oGPCR classiﬁed as other (Supple-
mentary Table 2) were of potential mouse to human translational
relevance, and interest for brain disorders.
We next mined the oGPCR-neuromap resource for these 25
oGPCRs, in order to extract mapping information, with a focus
on brain centers that govern cognition, motivational drive and
emotional processing, whose deregulation is known to cross-cut
most psychiatric symptoms (Fig. 4, top right) and are highly
studied in preclinical neuroscience research45–48. A selection of
sections is shown in Fig. 4 with most remarkable expression
patterns, and the potential relevance to the disease areas of
addiction and depression are detailed below as an example.
Cortical areas involved in decision-making and inhibitory
controls, particularly in relation to reward learning and emotional
experiences, include the orbital (OFC) and prefrontal (PFC)
cortices45,49, and their function is heavily impaired in both
addiction50 and depression51. OFC shows sparse patterns for
Gpr17, Gpr37, Gpr39, and Gpr125 (Adgra3), whereas Gpr26,
Gpr63, Gpr85, Gpr123 (Adgra1), and Gprc5c are dense throughout
this brain region (Supplementary Figure 3, top panel). Meanwhile
the nearby PFC (Fig. 4, top left) contains sparse distribution
pattern for Gpr17, Gpr37, and Gpr176. Some prefrontal oGPCR
transcripts show a cortical layer pattern, Gpr88 and Gpr153, while
others appear broadly expressed across cortical layers, i.e., Gpr27,
Gpr39, Gpr63, Gpr85, Gpr123 (Adgra1), Gpr125 (Adgra3), and
Gprc5c.
The striatum is composed of the dorsal CP and the ventral
ACB, which are main projection sites for dopamine neurons from
SN and VTA, respectively, and fulﬁll different functions. In the
CP, which controls motor responses and is also involved in
compulsive-like behaviors characterizing drug abuse52, we ﬁnd
Gpr17, Gpr37, Gpr39, and Gpr153 are sparsely localized while
Gpr26, Gpr27, Gpr88, Gpr161, and Gprc5c are broadly expressed
throughout the region (Supplementary Figure 3, middle). In the
ACB, the main center for reward and motivated behaviors53,54,
Gpr17 and Gpr37 feature a sparse pattern whereas Gpr26, Gpr27,
Gpr39, Gpr88, Gpr161, and Gprc5c are more widely distributed
(Fig. 4, middle left). Remarkably, Gpr101 not seen in the dorsal
striatum is found to be restricted in the shell of the ACB, a
compartment implicated in both drug and food reward46,55.
The habenula is an epithalamic structure composed of a lateral
(LHb) and medial (MHb) part, which has attracted increasing
attention in both areas of addiction and depression, for a role in
the anticipation of aversive outcomes (LHb, see Proulx et al.56
and Bromberg-Martin et al.57) and more generally for mediating
aversive states57–59. Receptors in the MHb with a sparse pattern
include Gpr17 and Gpr37 whereas Gpr26, Gpr27, Gpr63, Gpr85,
Gpr151, Gprc5b, and Gprc5c exhibit a dense expression pattern
(Fig. 4, bottom left). Of interest, Gpr151 was not detected in any
other brain region.
The hypothalamus, an area with accumbal inputs and outputs
to VTA, directs food reward, motivation, and stress response via
hypothalamic pituitary axis (HPA)46,60. Neurobiological adapta-
tions to stress are now well-accepted environmental triggers of
Fig. 3 Correlation analyses of DIG-ISH data with public genome-wide microarray datasets. a Expression proﬁles for 60 oGPCR in 12 mouse brain regions,
found in both mouse DIG-ISH data from this study (Left panel orange (high) to dark blue (low) and Fig. 2a) and mouse microarray data fro the BrainStar
platform (http://brainstars.org/ BrainStars, Riken, Japan)35 (middle panel, yellow (high) to light blue (low)). b, Expression proﬁles for 56 oGPCRs in 15
brain regions, found in both DIG-ISH from this study (left, orange (high) to dark blue (low) color scale) and Allen Brain’s human data (middle, magenta
(high) to cyan (low) color scale). a, b, Clustering shows best similar (top) to less-well correlated (bottom) oGPCR expression patterns. To the right of each
oGPCR comparison, a grayscale gradient shows Pearson correlation coefﬁcients (r) from positive (white) to inverse (black) correlation coefﬁcients, scale−1
to 1.0. oGPCRs with statistically signiﬁcant similar correlation coefﬁcients are indicated as ***P < 0.001, **P < 0.01, *P < 0.05. Except for Gpr68 in b, no gene
proﬁle comparison showed signiﬁcant difference according to students t-tests (Supplementary Table 1). OB, olfactory bulb; Ctx, cortex; ACB, nucleus
accumbens; CP, caudate putamen; HPF, hippocampal formation; BLA, basal-lateral amygdala; CeA, central extended amygdala; Hy, hypothalamus; Hb,
habenula; Th, thalamus; VTA, ventral tegmental area; SN, substantia nigra; Mb-other (general midbrain excluding aforementioned areas), Pn, pons; Cer,
cerebellum. oGPCRs were excluded from analysis if the regional expression did not vary or the oGPCR was not found in the public dataset. c Correlation
between Pearson coefﬁcients for 56 shared oGPCRs in a, b is shown. The majority of oGPCRs (34) show positive correlations in both datasets (top right
quadrant). Purple ﬁlled circles represent 23 of the 25 selected oGPCRs (Supplementary Table 2) for nanoString analysis in human brain samples. Gpr139
and Gprc5c were not available for correlation. Pearson correlation coefﬁcient was statistically signiﬁcant, r was 0.4987, ***P-value < 0.0001
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depression and addiction and GPCRs, such as CRF, which
modulate those responses are emerging pharmacological targets.
The hypothalamic oGPCR panel shows a sparse pattern for
Gpr17, Gpr50 and Gpr98 (Supplementary Figure 3, bottom).
Whereas, Celsr3 (Adgrc3), Gpr101 and Gpr176 are densely
localized throughout several hypothalamic nuclei. Interestingly,
around the third ventricle a dense layer of cells feature labeling
for only Gpr50 and Gpr98. Notably, Gpr50 was only detectable in
this region of the brain.
Long hailed as the primary seat of emotional responses, fear
and anxiety, the amygdala, is composed of several subnuclei with
diverse functions, BLA having roles in directing both negative and
positive valence and the CeA primarily involved in the negative
responses to fearful, stressful and drug-related stimuli61–64. DIG-
ISH shows Gpr17 and Gpr37 are expressed sparingly in the
neighboring BLA and CeA and Celsr3 (Adgrc3), Gpr26, Gpr161
show even distribution across the amygdala (Fig. 4, top right).
Remarkably, Gpr27, Gpr39 and Gpr63 show enriched expression
in the BLA whereas Gpr101 is enriched in the CeA.
The hind-midbrain houses several monoaminergic-rich nuclei.
Among them, VTA and SN are the major nuclei for dopaminer-
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control motor activity (SN), reward and motivation (SN and
VTA)48,65. While SN neuronal loss is a main feature of
Parkinson’s and Huntington’s diseases66–68, VTA dysfunction
strongly impairs hedonic homeostasis and motivation, a hallmark
of both addiction and depression46,47. The midbrain panel shows
Gpr26, Gpr39 and Gpr98 (Adgrv1), Gpr63, Gpr108, Gpr125
(Adgra3) and Gprc5c are found throughout the SN and VTA
though Gpr17 and Gpr37 are parsimoniously expressed (Fig. 4,
middle right). The serotonin-rich dorsal raphe (DRN) rich, is
another monoaminergic nucleus in the midbrain. Serotonin is
rewarding as it regulates mood and drugs that increase it act as
anti-depressants46,69,70. Therefore, dorsal raphe oGPCRs are
probable targets for dysfunctional reward systems and mood
disorders. Brain mapped oGPCRs enriched in the raphe show
dense localization for Gpr39, Gpr63, Gpr150, Gpr176, Gprc5c and
sparse cell pattern for Gpr98 (Fig. 4, bottom right).
Expression datasets are currently available for these 25 selected
oGPCRs in public resources. We further compared our ISH
mapping dataset with three mouse databases, including one qPCR
dataset7 [https://kidbdev.med.unc.edu/databases/ShaunCell/
home.php] and two ISH resources (GENSAT38 [http://www.
gensat.org/bgem_ish.jsp] and Allen brain37 [http://mouse.brain-
map.org/search/index]). Correlation analysis revealed signiﬁcant
positive Pearson correlations for 6 out of 25 (24%) for the qPCR
dataset, 7 out of 10 (70%) for the GENSAT dataset and 10 out of
22 (45%) for the Allen brain dataset (Supplementary Fig. 4 and 5).
In this comparison, datasets with the least similarity were also the
most technically different (ISH vs. qPCR), conﬁrming the critical
advantage of the ISH resource we have created here that
integrates two independent ISH analyses.
We next proceeded to examine the above selected oGPCRs in
human postmortem brain tissue, using a highly sensitive method
for gene expression analysis.
Focusing on these 25 oGPCRs in the human brain. The
nanoString digital multiplex nCounter assay71 directly ampliﬁes
each gene by a unique barcode permitting sensitive and reliable
quantiﬁcation as demonstrated by highly positive correlation of
technical replicates (Pearson r= 0.9984, P < 0.0001, 95% CI
0.9964–0.9993; Supplementary Fig. 6, and see Methods). Human
brain tissue was obtained from the Douglas Brain Bank http://
douglasbrainbank.ca/ and included 4–13 individual subjects that
had died suddenly from accidental or natural causes. To the best
extent possible, we dissected brain areas corresponding to mouse
brain areas of interest in this study. Samples were obtained from
14 different brain regions: orbital frontal cortex (OFC; BA11, n=
7), prefrontal cortex (PFC; BA9-10, n= 9), motor cortex (MoCtx;
BA4, n= 9), somatosensory cortex (SSCtx; BA1, 2, 3, n= 9),
nucleus accumbens (ACB, n= 9), caudate putamen (CP n= 13),
habenula (Hb, n= 4), thalamus (Th+Hb, n= 9), Medulla (Med,
n= 7), substantia nigra (SN, n= 7), Pons (Pn, n= 13) midbrain
(Mb, n= 6), ventral tegmental area (VTA, n= 6) and cerebellum
(Cer, n= 9). Data from this experiment are also available at
http://ogpcr-neuromap.douglas.qc.ca.
Hierarchical clustering of genes for individual subject sample
RNA counts is displayed in Fig. 5a. A ﬁrst observation is the high
homogeneity of oGPCR expression across individuals within a
given region reﬂecting low interindividual variability, and likely
therefore the high quality of the samples. A second observation is
the very distinct expression pattern for each oGPCR, as
previously observed in the mouse brain. A closer look at the
brain areas that govern emotional and cognitive functions
revealed several clusters of oGPCRs. For example, a cluster
composed of GPR161, GPR153, GPR123 (ADGRA1), GPR26,
GPR162, and GPR68 shows localized cortical and thalamic
oGPCRs, with little to no striatal expression (Fig. 5b, top).
GPR27, GPR88, GPR98 (ADGRV1), GPR101, GPR139 and
GPR149 are well detected in both striatal sub-regions (CP and
ACB), GPR101 being higher in ACB, but only GPR27, GPR88,
GPR98 (ADGRV1) also show signiﬁcant cortical expression
(Fig. 5b, middle). Finally, in the midbrain, GPR161 and GPR26
show expression restricted to VTA and SN, whereas GPR108,
GPR125 (ADGRA3), GPR37, GPRc5c, GPR39 and GPRc5b are
widely expressed across midbrain regions (Fig. 5b, bottom).
Translatability. We ﬁnally compared our mouse and human
datasets, in order to evaluate translatability of the mouse resource.
We combined DIG and RNAscope ISH expression data in the
mouse (Fig. 5c, left), and grouped the individual human subject
data (Fig. 5c, right), to examine oGPCR expression proﬁles in
eight brain regions including Ctx (OFC, PFC, MoCtx, SSCtx),
ACB, CP, Hb+ Th, Mb+VTA+ SN. GPRC5C was excluded
from this analysis, due to homogenous expression across all the
considered regions in the ISH datasets. For all the oGPCRs,
Student’s t-test showed no statistical difference across mouse and
human distribution proﬁle (Supplementary Table 1). Further,
Pearson correlation analysis revealed that 71% oGPCRs were
positively correlated, among which 4 (GPR151, GPR88, GPR149,
and GPR123 (ADGRA1)) showed statistically signiﬁcant similarity
(Pearson correlation, r from 0.8067 to 1, P values from 0.0155 to
Fig. 4 oGPCRs in brain centers relevant to cognition, motivational drive and emotional processing. Top right, a sagittal scheme shows high expression sites
for the 25 oGPCR subselection. A color is assigned to each brain region, and ISH image panels show expression patterns of remarkable oGPCRs in these
regions (see Supplementary Figure 3 for OFC, CP, and Hy). Top left panel, prefrontal cortex (PFC), critical for cognition, reward learning and inhibitory
controls, expresses Gpr17, Gpr27, Gpr37, Gpr39, Gpr63, Gpr85, Gpr88, Gpr123 (Adgra1), Gpr125 (Adgra3), Gpr153, Gpr176, and Gprc5c. Middle left panel,
oGPCR expressed in the nucleus accumbens (ACB), a key center for reward and motivation, are Gpr17, Gpr26, Gpr27, Gpr37, Gpr39, Gpr88, Gpr101, Gpr161,
and Gprc5c. Bottom left panel, habenula (Hb), an area critical for reward valuation, aversive processing and decision-making shows Gpr17, Gpr26, Gpr27,
Gpr37, Gpr63, Gpr85, Gpr151, Gprc5b, and Gprc5c expression. Top right panel, amygdala, a major center processing fear and negative affect, expresses Celsr3
(Adgrc3), Gpr17, Gpr26, Gpr27, Gpr37, Gpr39, Gpr63, Gpr101, and Gpr161. The basal lateral amygdala (BLA) is delimited by a white dashed line from the
central extended amygdala (CeA). Middle right panel, oGPCRs expressed in midbrain dopaminergic nuclei (VTA, ventral tegmental area; SN, substantia
nigra) central for movement and reward-related behaviors, are Gpr17, Gpr26, Gpr37, Gpr39, Gpr63, Gpr98 (Adgrv1), Gpr108, Gpr125 (Adgra3), and Gprc5c.
Bottom right panel, the serotonergic dorsal raphe nuclei (DRN), a main brain center for emotional responses and depressive states, shows expression of
Gpr39, Gpr63, Gpr98, Gpr150, Gpr176, and Gprc5c. The 1.25× insets show whole ection view at Allen brain atlas levels #32-40 (PFC), #43-47 (ACB), #65-71
(Hb), #68-75 (BLA/CeA), #81-89 (Mb-VTA/SN), and #98-105 (DRN) with a black box outlining the corresponding magniﬁed area. Scale bar for 1.25× is 1
mm and 10× is 100 µm. White arrows demonstrate sparse DIG labeling pattern for Gpr17, Gpr37, Gpr39, Gpr98, and Gpr176. Ctx, Cortex; CP, caudate
putamen; Mb, midbrain; Hy, hypothalamus; ac, anterior commissure; sh, shell; MHb, medial habenula; LHb, lateral habenula; PVT, paraventricular thalamus;
DRN, dorsal raphe nucleus
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<0.0001, also see Supplementary Table 3). Considering potential
discordant expression patterns, only 7 oGPCRs (GPRC5B, GPR50,
GPR161 GPR176, GPR125 (ADGRA3), GPR63, and GPR39)
showed inverse correlation, but none of them reached sig-
niﬁcance. For the latter oGPCRs, discrepancies in expression
proﬁles between mouse and human brains may arise from gen-
uine distribution across species or to the limited sampling in the
human dataset. Overall, the high level of well-correlated oGPCR
expression patterns demonstrates great promise for transfer
between mouse models to human diseases.
Discussion
This is the ﬁrst public brain oGPCR mapping resource to our
knowledge. This study reports in-depth anatomical expression
analysis in the mouse brain for each oGPCR, extensive compar-
ison of the data with publicly available gene expression databases
and, ﬁnally, the quantitative expression analysis of selected can-
didates in samples from the Douglas human brain bank.
Although mRNA transcript levels do not necessarily reﬂect levels
of protein expression72, any detectable oGPCR in principle can
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is a starting point to predict gene function73,74. We anticipate that
the combined datasets, all-available at the resource http://ogpcr-
neuromap.douglas.qc.ca, will be of valuable use to the neu-
roscience community in efforts to position oGPCRs based on
their expression patterns and their conservation between mouse
and human brains.
Our database has characteristics that distinguish this
resource from other public information. With regards to
oGPCR spatial anatomy in the mouse brain, only two resources
are available. GENSAT (5000 genes) is a mouse ISH database
focused on developmental gene expression changes across the
whole genome (http://www.gensat.org/bgem_ish.jsp), and as of
today, contains only 27 brain oGPCRs. Meanwhile, Allen brain
(http://mouse.brain-map.org/) has carried out large-scale ISH
experiments for about 20,000 genes in the mouse brain, and
these include most oGPCRs (except for Gpr27). However,
because of the high throughput nature of this massive enter-
prise, coronal sections are lacking and expression is undetect-
able for approximately half of oGPCRs. Our study reports 78
oGPCR expression proﬁles, ﬁne-mapped throughout the mouse
brain with optimized probes, and thus deﬁnitely characterizes
the expression pattern of each oGPCR transcript with high
precision. Importantly, our study combines two ISH-based
mapping approaches. We used both the classic histochemical
detection method (DIG-ISH), which yielded semi-quantiﬁable
datasets (Fig. 2a), and the newer high ampliﬁcation ISH method
RNAscope44. Overall, abundant oGPCRs transcripts were reli-
ably detected with both ISH methods, and the two datasets
showed consistent patterns based on manual observation (and
see http://ogpcr-neuromap.douglas.qc.ca). The low abundant
oGPCRs undetectable by DIG-ISH, such as Gpr139, Gpr149,
and Gpr162, were easily detected with RNAscope providing
expression patterns with cellular resolution for oGPCRs that
otherwise remained undetected in large-scale approaches
(Supplementary Figure 2).
Key information needed to design oGPCR projects involve
determining cell subtypes. We therefore searched an existing
cortical RNAseq database43 for all brain oGPCRs across 7 brain
cell types. Indeed, this cortical centered dataset is only a starting
point and oGPCRs may potentially be expressed in different cell
types depending on the brain structure. Another critical aspect of
this study is the correlation analysis with existing information.
Several approaches have been used to map gene expression in the
brain75, and these involve either ISH-based mapping methods, as
performed in this study, or microarray-based technologies
applied to microdissected brain regions (see Komatsu et al.33,
Kasukawa et al.35 and http://human.brain-map.org/) that provide
quantitative information on gene expression, but limited spatial
resolution.
Transcriptome expression data provide information that is
fairly distinct in nature from ISH data, but because the infor-
mation is available, we converted our ISH mapping results into
semi-quantitative information to cross-validate mouse data
(mouse/mouse) and also initiate cross-species comparison
(mouse/human). We found that our data are well aligned with
publicly available microarray mouse (BrainStars) and human
(Allen Brain) datasets. In fact, ~65% of oGPCRs were detected in
both our ISH study and the DNA microarray databases. Further,
48 (80%) and 39 (70%) oGPCRs transcripts showed comparable
expression proﬁles in mouse/mouse (Fig. 3a) and mouse/human
(Fig. 3b) comparisons, respectively. This indicates a high degree
of consistency for oGPCR expression proﬁles across multiple
detection techniques in the mouse, as well as a high level of
conservation from mouse to human (Fig. 3c). We therefore are
conﬁdent that the database provided by the present study offers a
strong basis for oGPCR evaluation in strategic decisions. To our
knowledge only one similar study was published, addressing
nuclear orphan receptors (Gofﬂot et al.74).
A third unique feature of our database is the inclusion of
detailed expression proﬁles for 25 oGPCRs in the human brain.
Selection of the 25 candidates was based on multiple criteria,
combining our own experimental data, correlation studies with
existing databases, current literature (Supplementary Table 2) and
our own interest in brain circuits that govern emotions and
cognition, and are possibly involved in addiction and mood
disorder pathologies. As human brain bank samples are limited,
we employed nanoString, a technology that engineers ﬂuorescent
barcoded nucleic acid probes that can be digitally imaged
allowing for as many as 800 genes to be probed in a single
sample71. The nanoString results yielded highly reproducible
quantiﬁcation for the 25 selected oGPCRs, with surprisingly low
interindividual variability (Fig. 5a). Of note, the latter experiment
identiﬁed a top-four oGPCR group with greatest similarity across
our own mouse and human data. In this group, Gpr88, Gpr123
(Adgra1), Gpr149, and Gpr151 all show signiﬁcantly correlated
proﬁles in mouse and human samples. All 4 receptors have in
common a primarily neuronal pattern according to our own ISH
images observation and a RNA-Seq database from the mouse
cortex (Table 1)43. Knowledge on these 4 oGPCRs largely varies:
Gpr88 is likely the most studied oGPCR in rodent models22–
26,28,76 but human data31 and reports on drug development29,30,77
are still limited; Gpr151 shows an intriguing localized expression
in the habenula, and is virtually undetectable anywhere else in the
brain and body35,78–81, and this receptor remains entirely open to
Fig. 5 Human expression proﬁles and cross-species comparison for 25 brain oGPCRs. a Hierarchical gene clustering shows expression levels of 25 oGPCRs,
determined by nanoString nCounter system, across the 14 human brain regions in samples obtained from 4 to 13 individuals. For each individual subject (S)
the sample is indicated by assigned identiﬁcation numbers for example subject 20 is “S20’. b Three panels from cluster (a) and outlined in white are
extracted here, to illustrate low interindividual variability, and highlight salient features of the cluster. Top, cortical and thalamic (Hb+ Th) restricted
oGPCRs form a cluster with low to no expression in the striatum. Middle, striatal (ACB and CP) oGPCRs can be subdivided into a striatal/non-cortical
cluster or corticostriatal cluster. Bottom, localized (VTA and SN) and widespread oGPCRs in the midbrain. c Comparison of mouse (combined DIG- and
RNAscope ISH) and human data from this study in eight brain centers. oGPCR distribution in the mouse ISH, (orange (high) to blue (low) mouse, n= 2)
was correlated to the grouped human nanoString data (magenta (high) to cyan (low), n= 4–13). Color bars below indicate expression levels for mouse
data (scale 2.48 to −1.78, interval 1) and human data (scale 2.48 to −1.49, interval 1). Clustering shows highly similar (top) to less-well correlated
(bottom) oGPCR expression patterns. Pearson correlation coefﬁcients (r) and their P-values are shown to the right for each oGPCR comparison in a
grayscale gradient heatmap from white (positive) to black (negative). Pearson correlation coefﬁcients, scale −1 to 1.0, interval 0.3. This analysis shows 17
positively correlated oGPCRs, among which 4 oGPCRs show signiﬁcant proﬁle similarity proﬁle, (Gpr151, Gpr88, Gpr149 and Gpr123 (Adgra1)) denoted by
***P < 0.001, **P < 0.01, and *P < 0.05. Annotations: Ctx, Cortex; orbital frontal cortex (OFC; BA11), prefrontal cortex (PFC; BA9-10), motor cortex (MoCtx;
BA4), somatosensory cortex (SSCtx; BA1,2,3), ACB, nucleus accumbens; CP, caudate putamen; Hb, habenula; thalamus (Th+Hb), Med, Medulla; SN,
substantia nigra; Pn, Pons; Mb, midbrain (Mb), VTA, ventral tegmental area; Cer, cerebellum. Gprc5c is not shown due to a lack of variation in expression
for the selected areas
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functional studies and drug discovery; Gpr149 shows broader
distribution in brain and spinal cord with a potential role in
sensory processing82, but is currently investigated in reproductive
biology because of substantial expression in ovaries83 Gpr123
belongs to adhesion GPCRs potentially implicated in brain
development, and genome wide association linked this receptor to
bipolar disorders84. Finally, 7 oGPCRs showed low homology
between mouse and human expression patterns, and further
studies will be required to determine whether animal models are
best appropriate to understand their role in human brain function
and disease.
In conclusion, selecting an oGPCR to undertake drug discovery
programs is a challenging issue, and predicting which may lead to
exploitable targets is difﬁcult. Our study is a step towards this goal
and the entire dataset should propel advancement in both oGPCR
and brain research.
Methods
Animals. Mice were housed in a temperature, humidity controlled animal facility
(21 ± 2 °C, 55 ± 10% humidity) on a 12 h dark-light cycle with food and water ad
libitum. C57/Bl6J male mice (n= 32) aged 10 weeks from Charles River were used.
All experiments were performed in accordance with the European Communities
Council Directive of 26 May 2010 and approved by the local ethical committee
(Com’Eth 2010-003 CREMEAS, 2003-10-08-[1]-58). All efforts were made to
minimize the number of animals used and their suffering.
Mouse tissue preparation. Mice were sacriﬁced by cervical dislocation, brains
were rapidly removed, frozen in OCT (Optimal Cutting Temperature medium,
Thermo Scientiﬁc) in a freezing mold and stored at −80 °C until use. Coronal brain
sections (25 μm) placed onto Superfrost® Plus slides (Thermo Scientiﬁc) were
obtained using a cryostat (Leica CM3050 S) at −20 °C. Mounted slices were stored
at −20 °C until use.
Riboprobe synthesis. To generate non-radioactive RNA riboprobes, commercially
available plasmids were purchased for each orphan GPCR gene (Supplementary
Data 1) from Source Bioscience (Nottingham, United Kingdom). Obtained plas-
mids were ampliﬁed and puriﬁed using the DNA puriﬁcation kit, NucleoBond®
Xtra Midi (Macherey-Nagel, Germany). Restriction endonuclease digestion reac-
tions were performed on 15 µg of plasmid DNA to linearize the vectors. Restriction
enzymes were chosen to obtain a ﬁnal probe length of 250-800 base pairs. Line-
arized vectors were puriﬁed and then subjected to in vitro transcription of anti-
sense ribopobes. One microgram of linearized DNA was transcribed using the
appropriate polymerase (Promega, Madison, WI, USA) and concomitantly
digoxigenin (DIG)-labeled by the 10× DIG RNA labeling mix (Roche, Germany)
according to the manufacturer’s instructions. The resulting Riboprobes were then
puriﬁed, the concentrations were quantiﬁed by spectrophotometry (Nanodrop
Labtech ND-1000) and quality was assessed with 1% agarose gel electrophoresis.
DIG in situ hybridization. Mounted brain slices were ﬁxed with 4% paraf-
ormaldehyde (Carlo Erba, Italy) in 1× phosphate buffered saline (PBS) (Sigma-
Aldrich) for 10 min, followed by acetylation with acetic anhydride (Sigma-Aldrich)
for 10 min with washing in PBS between steps. Afterward, slides were submitted to
successive dehydration baths: EtOH 60%, 70, 95, 100%, chloroform, EtOH 100,
95%. After drying the slides, hybridization overnight with 150 ng of probe per slide
was carried out at 70 °C. Sections were placed into 5 × SSC solution at room
temperature, followed by two washes in 0.2 × SSC, 1 h at 70 °C and 5min at room
temperature. After three washes in Tris/NaCl, blocking in normal goat serum
(Sigma) was done at room temperature for 1 h. Anti-DIG antibody (1/2500, Roche,
Germany) was added and incubated for 2 h at room temperature followed by 3
washes in Tris/NaCl and exposure with NBT (nitroblue tetrazolium, Roche, Ger-
many) and BCIP (5-bromo-4-chloro-3-indolyl phosphate, toluidinium salt Roche,
Germany) color substrates. After washes in water and drying, slides are mounted
with Pertex (Microm, France) and stored at room temperature. Image acquisition
was performed with the slide scanner NanoZoomer 2 HT (Hamamatsu, Shizuoka,
Japan) all the analysis was done on NDP View software (Hamamatsu, Shizuoka,
Japan). Control probes were included in each experiment. Negative controls were
treated with hybridization buffer lacking probes and probes for Oprm1, Penk, or
Gpr88 were included as positive controls (Supplementary Fig. 1a, upper panel).
RNAscope® in situ hybridization. A high ampliﬁcation system single molecule
detection ISH method, RNAscope® (Advanced Cell Diagnostics (ACD), Hayward,
California), was used for ultrasensitive detection and visualization of weakly
expressed mRNA, in brain tissue prepared with the same methods as tissue used for
DIG labeled riboprobe ISH (see above). All mouse speciﬁc probes were synthesized
by the manufacturer. Positive (mouse Ppib) and negative (DapB) control probes
were included in each experiment (Supplementary Fig. 1a, lower panel). RNAscope
experiments were performed according to the manufacturer’s instructions for fresh
frozen sections. Brieﬂy, sections were ﬁxed in 4% formaldehyde in 1× PBS over-
night at 4 °C and dehydrated in successive 3 min baths of ethanol (60, 75, 95, 100%)
and chloroform. After drying, two steps of pretreatment were performed, including
a 16-min step of protease digestion. Hybridization with speciﬁc probes was then
performed for 2 h at 40 °C, followed by six steps of ampliﬁcation. Two washes of 2
min were observed between each ampliﬁcation step. Fast Red was used as a
chromogen for the exposure step, which was monitored from 10 to 25 min at room
temperature under microscopic control. A counterstain included with the kit was
used in ISH early-on but obstructed distinguishing the red oGPCR stain from the
counterstain, (Supplementary Fig. 1b, lower panel Gpr88) and was removed for
subsequent experiments. After washing in water and drying, slides were mounted
with Ecomount (Biocare Medical, Concord, CA, USA) and stored at room tem-
perature. Image acquisition was performed with a slide scanner NanoZoomer 2 HT
(Hamamatsu, Shizuoka, Japan) all the analysis was done on NDP View software
(Hamamatsu, Shizuoka, Japan).
ISH scoring and public database comparative analysis. DIG-ISH and RNAscope
mapping analysis was adapted from the classiﬁcation of GenePaint annotation pro-
cedures (http://www.genepaint.org/) and previously described74. Manual annotation
of expression across brain regions, identiﬁed on the basis of published brain atlas,
Allen Brain Atlas (ABA)37, of expression are deﬁned: 3.5 as strong with color pre-
cipitate completely ﬁlling the cells, 2.5 as moderate detection with color precipitate
ﬁlling half of cell, 1.5 as weak detection and 0.5 as no detectable level above back-
ground, (Supplementary Fig. 1b, upper DIG-ISH and lower RNAscope). All images
were scored by two independent observers. Final scoring was the compilation of the
two independent scores. Multiple probe sets per oGPCR, if any, were averaged before
further analysis. As labeling intensities may differ between probes, scoring was per-
formed based on relative intensities across all brain sections for each probe. DIG-ISH
resulting scores were submitted to hierarchical cluster analysis for gene axis with
Euclidean distance and average linkage using TreeView and Cluster 3 software85.
Group comparison analysis was performed with the mouse DNA microarray
data from the BrainStars database (http://brainstars.org/)35 included 48 punched
regions compiled into 12 regions to match our analyzed regions for 60 oGPCRs.
Analysis of human ABA complete normalized microarray datasets were compiled
from six subjects and 106 brain regions were merged into 15 brain regions (http://
human.brain-map.org/static/download) for 56 oGPCRs. Regions left out of
correlations were due to a lack of corresponding regions in datasets and
categorization of sub-nuclei were according to ABA classiﬁcation. In the event of a
gene having multiple probe sets data were ﬁrst averaged, followed by region and
donor averaging. To facilitate group comparison, the datasets were ﬁrst converted
into gene Z-scores (regional expression is expressed in terms of standard deviations
(SD) from the mean of each gene [Z-score= (oGPCR region—mean of oGPCR
regions)/SD of oGPCR regions].
To determine oGPCR cell pattern in the brain, we searched the Brain RNA-Seq
database (https://web.stanford.edu/group/barres_lab/brain_rnaseq.html)43 for all
92 oGPCRs (Table 1). Shown is the category of cell subtype (neurons, astrocytes,
microglia, endothelial cells, pericytes, or various maturation states of
oligodendrocytes) followed by oGPCRs with the highest Fragments Per Kilobase of
transcript per Million (FPKM) mapped reads. If FPKM were below 1.0, virtually
undetectable was written.
To compare the mouse ISH public databases for the selected 25 oGPCR
subgroups, gene z-scores were computed for each gene per technique. All of the
selected oGPCRs were available in the qPCR dataset obtained from Regard et al.
supplementary ﬁles but in only 7 of 11 regions. 14 oGPCRs were not found and 1
was undetectable in adult GENSAT-ISH dataset. The ten selected oGPCRs found at
GENSAT are available only as images. Thus, we used the same criteria that we
applied in our study’s ISH mapping to semi-quantify the GENSAT dataset and
converted them to Z-scores. Allen brain mouse ISH data for all but 3 oGPCRs
(Gpr139, Gpr153, and Gpr27) was obtained as “Raw expression values” from the
website and converted into gene Z-scores for the 11 regions. Finally, DIG-ISH
quantiﬁcation from this study (Fig. 1) was converted into gene Z-scores for the 11
regions. Gpr63, Gpr139, Gpr149, and Gprc5c were compared using this study’s
RNAscope ISH quantiﬁcation.
Human brain tissue dissections. Postmortem (PM delay 6–24 h) tissues from 14
brain regions of 4–13 (dependent on region availability) male adult individuals
were obtained from the Suicide section of the Douglas – Bell Canada Brain Bank
(Douglas Mental Health University Institute, Montreal, Quebec, Canada). The
subjects had died suddenly from accidental or natural causes and were aged 20–55.
Dissections were performed on fresh frozen 0.5 cm-thick coronal sections with the
guidance of a human brain atlas86. Samples were prepared from the following
regions: orbital frontal cortex (OFC; BA11), prefrontal cortex (PFC; BA9-10),
motor cortex (MoCtx; BA4), somatosensory cortex (SSCtx; BA1,2,3), nucleus
accumbens (ACB), caudate putamen (CP), habenula (Hb), thalamus (Th+Hb),
Medulla (Med), substantia nigra (SN), Pons (Pn) midbrain (Mb), ventral tegmental
area (VTA), and cerebellum (Cer). Ethical approval (Protocol 15/04) for this study
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was obtained from the Institutional Review Board of the Douglas Mental Health
University Institute.
Human RNA preparation and integrity analysis. Human total RNA was isolated
using NucleoZol (Macherey-Nagel, Düren, Germany). A NanoDrop ND2000
(ThermoFisher, Waltham, MA, USA) spectrophotometer was used to determine
RNA quantity and quality. RNA integrity numbers (RIN) were measured by
automated electrophoresis with the 2200 TapeStation system (Agilent, Santa Clara,
CA, USA). Low RNA concentrations and integrity (RIN < 4) were excluded from
analysis. RINs higher than 5 were considered good quality and samples with a RIN
higher than 8 were considered perfect87.
NanoString. Experiments were performed at the Jewish General Hospital Molecular
Pathology Center (Montréal, QC, Canada) using NanoString nCounter targeted gene
expression proﬁling as described previously88. In brief 5 µl of 20 ng/µl total RNA was
hybridized with the reporter and capture probes at 65 °C for overnight. Probes were
custom designed to target 25 oGPCRs and 5 housekeeping genes as internal controls:
GAPDH, ACTB, HPRT1, RPL19, RPL0. The samples were then processed with the
nCounter Prep Station to purify the hybridized targets and afﬁx them to the cartridge
for imaging with a CCD camera. Barcodes were counted for each target molecule. The
data were analyzed using the nSolver version 3.02 (nanoString Technologies). Non-
speciﬁc binding was subtracted by measuring binding densities of negative control
ERCC RNA probes that target genes not expressed in human tissues. Positive control
normalization parameters were followed as indicated by the manufacturer. House-
keeping genes used for normalization was dependent on low coefﬁcient of variance (%
CV). Finally, Z-scores for each gene were used to facilitate comparison with the other
datasets.
Data analysis. For all correlations, datasets were converted to Z-scores. ISH scores,
BrainStars microarray, Allen Brain microarray, and normalized nanoString data
were ﬁrst converted into gene Z-scores (regional expression is expressed in terms of
standard deviations (SD) from the mean of each gene [Z-score= (oGPCR region—
mean of oGPCR regions)/SD of oGPCR regions]. Statistical analyses were carried
out using Prism 6.0 or 7.0 and heatmaps were done with Prism 7.0 software
(GraphPad Software, Inc). When the P-value was less than 0.05 data was con-
sidered as statistically signiﬁcant.
Data availability. Data used in this study were retrieved from RNA Riboprobe
accession numbers GenBank NCBI (https://www.ncbi.nlm.nih.gov/genbank/), the
Brain RNA Seq website (https://web.stanford.edu/group/barres_lab/brain_rnaseq.
html), the BrainStars database (http://brainstars.org/), and the Allen Institute
human gene expression database (http://human.brain-map.org/). The mouse ISH
datasets generated and analyzed in this study are freely available at (http://ogpcr-
neuromap.douglas.qc.ca). The human nanoString data generated and analyzed in
this study are freely available to download at (http://ogpcr-neuromap.douglas.qc.ca).
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